Mondobiotech was a Swiss-based biotechnology company focused on developing human peptides as medicaments for patients affected by rare diseases.
Mondobiotech was founded in 2000 by Fabio Cavalli and Dorian Bevec.
[1] The company listed on the Zurich exchange in 2009.
[2] In March 2012, Pharma Times in exclusive negotiations with Pierrel Research, the contact research division of the Italian company Pierrel.
[3] Mondobiotech created drugs for rare diseases.